1 Antibiotic utilisation and the impact of antimicrobial resistance action plan on

2 prescribing among older adults in New Zealand between 2005 and 2019

- 3 Authors
- 4 Tichawona Chinzowu (MSc), Department of Life Sciences, University of Bath, United
- 5 Kingdom
- 6 Te-yuan Chyou (PhD), Department of Biochemistry, University of Otago, Dunedin,
- 7 New Zealand
- 8 Sandipan Roy (PhD), Department of Mathematical Sciences, University of Bath.
- 9 Hamish Jamieson (PhD), Associate Professor and Geriatrician, University of Otago
- 10 Christchurch, Department of Medicine; Burwood Hospital, Christchurch, New
- 11 Zealand
- 12 Prasad S Nishtala (PhD), Department of Life Sciences, University of Bath, United
- 13 Kingdom
- 14 and
- 15 Centre for Therapeutic Innovation, University of Bath, United Kingdom
- 16
- 17 Running title: Antibiotic utilisation patterns
- 18

19 Address correspondence to:

- 20 Tichawona Chinzowu, Department of Pharmacy and Pharmacology, University of
- 21 Bath, Bath
- 22 BA2 7AY, United Kingdom
- 23 Email: tc888@bath.ac.uk
- 24
- 25 **Word count**: 3114 (excluding references) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 Abstract

28

Purpose: The objectives of this study were to examine the overall utilisation of systematic antibiotics and the impact of the launch of the antimicrobial resistance action plan in older adults (65 years or more) living in New Zealand between 2005 and 2019, using data from a national database (Pharmaceutical collections), stratified by antibiotic class, patient age, and sex.

Methods: Population-level systemic antibiotic dispensing data for older adults in New Zealand was analysed using repeated cross-sectional analysis between 01/01/2005 and 31/12/2019. Data were extracted on the prescribed systemic antibiotics using a unique identifier for each case. Antibiotic utilisation was measured in DDD/TOPD values. In addition, an interrupted time series (ITS) analysis using the autoregressive integrated moving average (ARIMA) models was performed to determine the impact of the antimicrobial resistance action plan.

Results: Most of the antibiotic classes included in this study showed a significant overall decrease in utilisation ranging from 38.64% for sulphonamides to 80.64% for fluoroquinolones compared to 2005. Systemic antibiotic utilisation decreased by 49.6% from the predicted usage between January 2018 and December 2019 following the launch of the antimicrobial resistance action plan. ARIMA model supported the reduction in utilisation with a step change of -0.2206 and slope change of -0.0029.

47 *Conclusions*: The ITS analysis has demonstrated that the intervention may have 48 hugely impacted the antibiotic utilisation rate among older adults. Further studies are 49 required to determine whether the reduced consumption rates of antibiotics are 50 associated with reduced rates of antibiotic-associated adverse drug events such as 51 acute kidney injury and haematological abnormalities.

52

Keywords: antimicrobial, consumption, prescribing, defined daily dose, elderly, time
 series, ARIMA model

55

56 Introduction

57

Inappropriate prescribing of antibiotics is an important driver of the rising global 58 antibiotic resistance and a direct threat to the safety of patients due to the increased 59 risk of adverse drug events such as acute kidney injury, haematologic, gastrointestinal, 60 dermatologic and hepatobiliary abnormalities [1-3]. Outpatient and community 61 utilisation of antibiotics is on the rise, with older adults (>65 years of age) receiving the 62 highest prescribing rate compared to any other age group [4]. In the United States, 63 older adults are one and half times more likely to receive antibiotics than younger 64 65 adults in a year [5, 6]. In over 46% of visits involving non-bacterial respiratory tract infections, adults ≥65 receive unnecessary antibiotics, most of which are broad-66 spectrum agents [7, 8]. This increased rate of inappropriate prescribing raises 67 concerns for older adults who are already at increased risk for serious adverse drug 68 events due to age-related physiologic changes, comorbidities, and polypharmacy [9]. 69 Antibiotics, as a class, are the third commonest cause of adverse drug events among 70 older adults. Nearly 15% of all emergency department visits for antibiotic-associated 71 adverse drug events occur in older adults [10]. 72

Specific antibiotic classes pose increased safety risks for older adults. For example, fluoroquinolones have been reported to put older adults at an elevated risk of serious adverse events, including tendon rupture, blood sugar disturbances, peripheral neuropathy, delirium and aortic dissection [11]. Macrolides, commonly prescribed to older adults, were associated with an elevated risk of cardiac arrhythmia and death, particularly in males [12]. Cotrimoxazole requires close monitoring in older adults due to the risk of pre-existing renal insufficiency necessitating dose adjustment [1].

There was a significant decrease in annual antibiotic usage between 2014 and 2018 80 81 among most countries in the world Health Organisation (WHO) Europe region, including the United Kingdom, Germany, and Finland [13]. In their study, Andersson 82 et al. [14] showed consistently higher antibiotic usage in Australia compared to 83 Sweden. In New Zealand, systemic antibiotic consumption increased from 17.31 to 84 25.79 DDD per 1000 per day between 2006 and 2014 [15]. In another New Zealand 85 study, systemic antibiotics' consumption increased by 2% between 2010 and 2015 86 87 among older adults [16].

For population-level health interventions, the interrupted time series (ITS) analysis is a valuable tool for evaluating their effectiveness, provided they were implemented at a well-defined time point [17]. Segmented regression is a commonly used approach for ITS analysis. However, it is not adequate in autocorrelation and seasonality [18]. An alternative method, the ARIMA model, can accommodate both seasonality and autocorrelation [18].

Few studies describe the utilisation of systematic antibiotics at the population level, 94 95 specifically among older adults in New Zealand, and how the utilisation rates respond to interventions primarily aimed at mitigating the development of antimicrobial 96 resistance. Therefore, the objectives of this study were to examine the overall 97 utilisation of systematic antibiotics and the impact of the launch of the antimicrobial 98 99 resistance action plan in older adults (65 years or more) living in New Zealand between 2005 and 2019, using data from a national database (Pharms), stratified by therapeutic 100 101 class, age, and sex, based on the World Health Organisation Collaborating Centre for Drug Statistics Methodology (WHOCC) Anatomical Therapeutic Chemical (ATC) 102 classification. 103

104

105 Methods

106

107 Study design

Population-level systemic antibiotic dispensing data for older adults in New Zealand was analysed using repeated cross-sectional analysis between 1st January 2005 and 31st December 2019. Data were extracted on the prescribed systemic antibiotics using a unique identifier for each case and analysed for utilisation in DDDs according to patients' antibiotic class, age, and sex. This study included dispensing claims data for all funded antibiotics by community pharmacies.

114 Data source

From 1st January 2005 to 31st December 2019, de-identified individual dispensing claims data for older adults (65 years and above) were extracted from the Pharmaceutical Collections [19, 20]. Pharmaceutical collections are the New Zealand Ministry of Health's national dispensing claims database which captures subsidised prescriptions dispensed by community pharmacies [21]. Antibiotics were categorised

using the ATC developed by WHOCC. The following antibiotic classes were included
in this study: penicillins (J01C), macrolides (J01F), cephalosporins (J01D),
tetracyclines (J01A), sulphonamides (J01E), fluoroquinolones (J01M),
aminoglycosides (J01G), and 'other antibiotics' (J01X) [22]. In addition, metronidazole,
nitrofurantoin, and vancomycin were classified as 'Other antibiotics' (J01X).

125

126 Data analysis

DDDs were computed for each antibiotic dispensed to an individual yearly and 127 normalised by age group, antibiotic class, and sex at a population level. In this study, 128 the DDD per 1000 older people per day (TOPD) measures the proportion of people 129 being treated with a daily dose of antibiotic dispensed within a defined study area per 130 1000 older people per day. Antibiotic utilisation by class, sex and age were also 131 measured in DDD/TOPD values. The DDDs were computed for each antibiotic utilised 132 by an individual yearly, per annual population size of New Zealand between 2005 and 133 2019. The R statistical software (version 4.2.0) was used in all analyses [23]. 134

135 Interrupted time series analysis

Using the R statistical software (version 4.2.0), we determined the effect of introducing 136 137 the antimicrobial resistance action plan in January 2018 in New Zealand on antibiotic prescribing and utilisation rates among older adults. We performed ITS analysis using 138 the ARIMA model [18] on monthly antibiotic utilisation rates to understand the effect 139 of the implemented national antimicrobial resistance action plan [18]. Monthly 140 DDD/TOPDs were computed above for the study period and population. The pre-141 intervention period was from January 2005 to December 2017, and the post-142 intervention period was from January 2018 to December 2019. 143

Firstly, the time series data was plotted to understand any patterns, including trends 144 and seasonal variations. Then, the forecast R package [23] was used to determine 145 p/P and q/Q parameters. Next, stationarity was induced using the first-order difference 146 where d = 1 and D = 1 for trend and seasonal differences, respectively. Next, we 147 plotted the autocorrelation and partial autocorrelation functions (ACF/PACF) of 148 stationarity data to view and confirm the ARIMA orders from the automated algorithms. 149 150 Finally, the Ljung-Box test [18] was used to test whether residuals for the model were white noise or not. 151

152 Counterfactual values for the post-intervention period were determined and plotted 153 together with observed values to visualise the impact of the intervention on the 154 antimicrobial utilisation rate among older adults.

155

156 **Results**

157

158 Overall trend

Table 1 shows the percentage change in the utilisation of funded systemic antibiotics among older adults between 2005 and 2019 in New Zealand. Overall systemic antibiotic utilisation decreased by 56.28% between 2005 and 2019, averaging an annual decrease of 4.02% (Table 1). However, utilisation remained high from 2005 to 2017, declining between 2018 and 2019 (Figure 1) following the implementation of the New Zealand Antimicrobial Resistance Action Plan [24].

- **Table 1**: Utilization of antibacterial agents (in defined daily dose per 1000 older
- people per day [DDD/TOPD] values) between 2005 and 2019.

Antibacterial class	Antibacterial name	Subsidized	WHO ATC classification	2005 DDD/TOPD	2019 DDD/TOPD	Change (%)
Aminoglycosides	Gentamicin sulphate ¹	Partly	J01GB03	0.0023	0.0015	-31.9
Subtotal	Tobramycin ²	Partly	J01GB01	0.0038 0.0059	0.0004 0.0019	-88.8 -68.0
Cephalosporins	Cefuroxime axetil₃	Partly	J01DC02	0.0092	0.0081	-12.0
	Cefaclor monohydrate	Yes	J01DC04	1.2259	0.7492	-38.9
	Ceftriaxone₄	Partly	J01DD04	<0.0001	0.0010	5215.2
	Cefalexin	Yes	J01DB01	0.0863	0.6281	627.8
Subtotal	Cefazolin	Yes	J01DB01	0.0031 1.3249	0.0016 1.3879	-50.0 4.8
Fluoroquinolones	Norfloxacin₅	Partly	J01MA06	1.0518	0.0381	-96.4
	Ciprofloxacin	Yes	J01MA02	0.9586	0.3490	-63.6
Subtotal				2.0104	0.3872	-80.7
Macrolides	Azithromycin	Yes	J01FA10	0.0017	0.1147	6640.7
	Clindamycin	Yes	J01FF01	0.9075	0.7210	-20.6

		Roxithromycin		J01FA06	1.8771	0.6620	-64.7	
		Clarithromycin	Partly	J01FA09	0.0662	0.0119	-82.1	
		Erythromycin ethyl succinate	Yes	J01FA01	1.8436	0.4295	-76.7	
		Erythromycin stearate	Yes	J01FA01	0.1696	0.0131	-92.3	
		Erythromycin (as lactobionate)	Yes	J01FA01	0.0001	<0.0001	-48.1	
Subtotal		, , , , , , , , ,			4.8659	1.952243	-59.9	
Other ant	tibiotics	Metronidazole	Yes	J01XD01	0.9267	0.3647	-60.7	
		Nitrofurantoin	Yes	J01XE01	1.2779	1.0226	-20.0	
		Vancomycin [,]	Partly	J01XA01	0.0029	0.0033	13.8	
Subtotal					2.2075	1.3906	-37.0	
Penicillins		Amoxicillin- clavulanic acid	Yes	J01CR02	4.9023	1.0866	-77.8	
		Amoxicillin	Yes	J01CA04	2.5529	1.2829	-49.8	
		Benzathine benzylpenicillin	Yes	J01CE08	0.1901	0.0071	-96.3	
		Dicloxacillin	No	J01CF01	0.0656	0	NA	
		Penicillin G	Yes	J01CE09	0.0017	0.0001	-91.2	
		Penicillin V	Yes	J01CE02	0.2428	0.0955	-60.7	
		Flucloxacillin	Yes	J01CF05	2.0635	1.3127	-36.4	
Subtotal					10.0188	3.7848	-62.2	
Sulphonamides		Co- trimoxazole	Yes	J01EE01	0.7813	0.4340	-44.5	
Subtotal		Trimethoprim	Yes	J01EA01	1.7506 2.5319	1.1192 1.5533	-36.1 -38.7	
Tetracycli <i>Subtotal</i>	ines	Doxycycline	Yes	J01AA02	5.6786 5.6786	2.0642 2.0642	-63.7 -63.7	
•	antibact	erial agents)			28.6440	12.5221	-56.3	
Notes:	1. Gentamicin sulphate subsidised only if prescribed for a dialysis or cystic fibrosis							
	patient or complicated urinary tract infection and the prescription is endorsed							
	accordingly.							
	2. Tobramycin subsidised only if prescribed for dialysis or cystic fibrosis patient and the							
		tion is endorsed a			-	-		
			- /					

3. Cefuroxime axetil subsidised only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.

175	4. Ceftriaxone subsidised only if prescribed for a dialysis or cystic fibrosis patient, or
176	the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the
177	treatment of suspected meningococcal disease, and the prescription or PSO is endorsed
178	accordingly
179	5. Norfloxacillin subsidised only if prescribed for a patient with an uncomplicated
180	urinary tract infection that is unresponsive to a first line agent or with proven resistance
181	to first line agents and the prescription is endorsed accordingly.
182	6. Clarithromycin subsidized for Helicobacter pylori infections only.
183	7. Vancomycin subsidized only if prescribed for a dialysis or cystic fibrosis patient or for
184	prophylaxis of endocarditis or for treatment of Clostridium difficile following
185	metronidazole failure and the prescription is endorsed accordingly.
186	
187	Source for notes 1-7: PHARMAC, Online Pharmaceutical Schedule. Available at:
188	https://schedule.pharmac.govt.nz/ScheduleOnline.php. Accessed on 03/06/2022.
189	

190 Most antibiotic classes included in this study showed a significant decrease in utilisation ranging from 38.64% for sulphonamides to 80.64% for fluoroguinolones. 191 192 However, cephalosporins showed a 4.76% increase in usage during the study period, and this was largely attributed to the increased utilisation of cephalexin and 193 ceftriaxone. Although macrolide utilisation decreased significantly, the utilisation of 194 azithromycin increased by just over 66 times that of 2005 by the end of 2019. 195 Vancomycin only showed an overall increase of 13.8% in utilisation during the study 196 period. In 2019, the top four single most utilised antibiotics were doxycycline 197 (DDD/TOPD = 2.06), flucloxacillin (DDD/TOPD = 1.31), amoxicillin (DDD/TOPD = 198 1.28), and trimethoprim (DDD/TOPD = 1.12) (Table 1). 199

200 Utilisation by antibiotic classes

Except for aminoglycosides and fluoroquinolones, all included antibiotic classes showed a steady increase in utilisation until 2016 (Figure 1), followed by a sharp decline. Fluoroquinolone utilisation started declining in 2012, while aminoglycoside utilisation remained very low. The most utilised antibiotic classes were penicillins (DDD/TOPD = 3.78), tetracyclines (DDD/TOPD = 2.06), and macrolides (DDD/TOPD = 1.95) (Table 1). The biggest reduction in utilisation between 2005 and 2019 was on fluoroquinolones, which dropped by 80.7% (Table 1).

208 Utilisation by antibiotic class and age

The total systemic antibiotic consumption increased with age but remained relatively steady from 2005 to 2017 (Figure 2). Penicillins were the most utilised antibiotics across all age groups. In addition, the DDD/TOPD for all classes, except aminoglycosides, increased with age.

213 Utilisation by antibiotic class, age, and sex

The rate of antibiotic consumption was constant in both males and females for all 214 antibiotic classes (except fluoroguinolones) and age groups, except for the 95 years 215 old and above males, whose consumption rate has been steadily increasing in all 216 antibiotic classes (Figure 3). Between 65 and 79 years of age, antibiotic utilisation was 217 similar for both sexes. Females had higher utilisation than males from age 80 to 94 218 years. Among those 95 years and above, males had greater utilisation than females. 219 Fluoroquinolone utilisation has been decreasing in all age groups for both males and 220 females as early as 2012, except among the 95 years and above males, where the 221 decrease in consumption started in about 2015. 222

223 Interrupted time series analysis

The observed data showed a slight upward trend and possible seasonality on analysis 224 (Supporting file, Figures S1, S2 and S3). Before the intervention, the visible trend and 225 seasonality determined stationarity by first difference (d = 1) and seasonal difference 226 (D = 1). According to the undifferenced and differenced ACF/PACF plots obtained, the 227 former showed autocorrelation at lag 12 (Supporting file, figure S4 and S5). After 228 running the automated algorithm in R, the best model selected was (3,1,0) (0,1,1) [12]. 229 Thus, autocorrelation order (p) was 3, the moving average order (q) was 0, the 230 autocorrelation order for the seasonal part (P) was 0, and the moving average order 231 for the seasonal part (Q) was 1. The p-value for the Ljung-Box test for white noise was 232 0.51 at 36 lags (Spporting file, figure S6); therefore, the chosen model had a good fit. 233 Figure 4 is the final ARIMA model showing predicted values in the absence of an 234 antimicrobial resistance action plan (counterfactual) compared to observed values. 235 The estimated step change was minus 0.2206 (95% CI: -0.4619 - 0.0207) and the 236 estimated change in slope was -0.0029 (95% CI: -0.0097 - 0.0039). 237

238239 Discussion

240

241 Overall trend

This study found that the overall utilisation of subsidised systemic antibiotics among 242 older people in New Zealand dropped by 49.6% of the predicted utilisation rate for 243 2018/2019 following the implementation of the antimicrobial resistance action plan 244 [24]. In a previous study, systemic antibiotic utilisation was reported to have increased 245 246 49% between 2006 and 2014 in New Zealand [15]. This increase is also reflected in this study, where utilisation of most antibiotic classes steadily increased until 2015 247 (Figure 1 and table 2). However, this was followed by a sharp decrease to more than 248 56% below the 2005 utilisation rate between 2018 and 2019. 249

We concluded that implementing the antimicrobial resistance action plan contributed 250 251 significantly, but not exclusively, to the significant drop in total antibiotic utilisation rates in New Zealand in 2018 and 2019. In 2015, Thomas [25] called for immediate action 252 to reduce antimicrobial prescribing in New Zealand, particularly in the community 253 where most infections were self-limiting. His recommendations included not 254 prescribing antibiotics where the infection was likely viral, not prescribing antibiotics 255 for sore throat in all over eighteen (except for Māori and non-Pacific ethnicities), 256 substituting amoxicillin-clavulanic acid with penicillin for Streptococcus pyogenes skin 257 infections, and no fluoroquinolones for urinary tract infections. These 258 recommendations were supported by the Antibiotic Consumption in New Zealand. 259 2006 - 2014 surveillance report [26]. Significant reduction in amoxicillin and 260 amoxicillin-clavulanic acid utilisation rates would greatly impact total antibiotic 261 utilisation since these two antibiotics contributed more than 42% of the total antibiotic 262 utilisation rates for the period 2006 - 2014 [26]. The utilisation of these penicillins, and 263 264 to a lesser extent macrolides and tetracyclines, followed a seasonal pattern with peaks during the winter months (June to August) and troughs during the summer months 265 (December to February) in New Zealand [26]. The highest use of penicillins was 266 reported among older adults of the Pacific Peoples, European (and other), Middle 267 Eastern, Latin American, and African (MELAA) ethnicities. The utilisation of amoxicillin 268 and amoxicillin-clavulanic acid doubled between 2006 and 2014, possibly overusing 269 270 due to overlapping clinical features of indicated conditions with viral infections [26].

The antimicrobial resistance action plan was developed through a collaboration of 271 various human, animal and agricultural stakeholders to respond to the ever-rising 272 global challenge of antimicrobial resistance [24]. The implementation would be spread 273 over five years from 2017, with the first year mainly for fact-finding, training, and 274 resource mobilisation before rolling out the activities from year two onwards. One of 275 the main objectives focussed on the optimisation of the use of antimicrobial medicines, 276 whereby in 2017, the focus was on investigating inequalities in antimicrobial 277 prescribing in community hospital settings and, from 2018, rolling out the appropriate 278 279 activities to reduce antimicrobial consumption while promoting appropriate prescribing began [24]. In our study, we, therefore, considered January 2018 as the date of starting 280 the measures recommended to reduce antimicrobial utilisation in New Zealand. 281

282 The ITS analysis, as shown in figure 4, has demonstrated that this intervention significantly impacted the antibiotic utilisation rate among older adults. The huge drop 283 284 in total antibiotic utilisation rate was probably due to a huge drop in prescribing amoxicillin or amoxicillin-clavulanic acid following the implementation of the action 285 plan. The Best Practice Advocacy Centre for New Zealand (BPACNZ) supported this 286 and noted a sustained decrease in dispensed oral antibiotic prescriptions per 1000 287 registered patients [27]. In 2018 and 2019, there was an average of 3% to 5% annual 288 drop in dispensed antibiotic prescriptions, according to the BPACNZ [27]. This 289 decrease was attributed to New Zealand's improved antimicrobial stewardship. Our 290 findings were further supported by Thomas et al. [28], who concluded that there was 291 an overall decrease in dispensing of antibiotics among adults 60 years or above in 292 New Zealand between 2015 and 2018. In their study, Thomas et al. [28] found that 293 community antibiotic dispensing, measured as defined daily doses per 1,000 294 inhabitants per day, decreased by 4.6% per year during 2015-2018, with large 295 reductions in dispensing of amoxicillin-clavulanate [28]. 296

In a recent study, overall antibiotic utilisation was consistently higher in Australia compared to Sweden between 2006 and 2018 [14]. In Australia, the overall utilisation was steady, ranging from 21.8 DDD/TOPD in 2006 to 22.2 DDD/TOPD in 2018, whereas Sweden experienced a 26.2% decrease in utilisation between 2006 and 2018. Compared to Australia and Sweden, our results showed that New Zealand's drop in overall antibiotic utilisation was the fastest, which could have been

necessitated by the government's strong response to the increasing global challenge
 of antimicrobial resistance in 2016 [29].

The top four most utilised antibiotic agents in 2019 were doxycycline, flucloxacillin, 305 amoxicillin, and trimethoprim (Table 1). This finding agrees with previous studies 306 where doxycycline and amoxicillin consistently appeared on the top list of heavily 307 consumed single antibiotics [14, 15]. However, in a separate US study, the top four 308 most used antibiotics among older adults (65 years or more) were azithromycin, 309 ciprofloxacin, amoxicillin, and cefalexin [30]. The differences in the usage of individual 310 antibiotics are possibly due to different local and national antibiotic stewardship 311 policies, treatment guidelines, subsidy arrangements, and non-adherence. [13, 31, 312 32]. 313

314 Utilisation by antibiotic class

This study showed that in 2019 the most utilised antibiotic classes were penicillins, tetracyclines, and macrolides (Table 1). Previous studies have also found penicillins, extended-spectrum penicillins and beta-lactamase sensitive penicillins as the most heavily consumed antibiotic classes in New Zealand, Australia, and Sweden, respectively [14, 15]. This general agreement in utilisation trends, by class, of systemic antibiotics may indicate an internationally improved antibiotic stewardship.

321 Utilisation by age group and sex

In this study, antibiotic utilisation rates generally varied with age and sex, increasing 322 in the older age group (Figure 2). Williamson et al. [15] also found that antibiotic 323 utilisation rates increased with age among the New Zealand population and were 324 significantly and consistently higher in females than males between 2006 and 2014. 325 Our study showed that antibiotic utilisation was similar for males and females between 326 65 and 79 years. However, females had a higher antibiotic utilisation rate than males 327 between the ages of 80 and 94, and men of 95 years and above had a higher utilisation 328 rate than women (Figure 3). Marguez et al.'s study support this finding that after age 329 65, men have higher innate and pro-inflammatory activity and lower adaptive activity 330 than women [33]. 331

332 Limitations

One of the major limitations of dispensing data is the lack of information on antibiotics' 333 indications and appropriateness. Therefore, adherence to antimicrobial therapy by the 334 patients is not captured and accounted for when using such datasets. We used data 335 for dispensing claims for funded antibiotics made by community pharmacies only, thus 336 possibly missing data on unfunded antibiotics prescribed to the study population 337 during the study period. Additionally, the Pharmaceutical Collections database does 338 not include information about medicines dispensed in hospitals [34], so antibiotic 339 exposure may have been underestimated if older adults received the drugs during 340 341 hospitalisation. Our post-intervention observation period was relatively short (from January 2018 to December 2019) and therefore might not reflect the true impact of the 342 intervention. Other factors besides the antimicrobial action plan may have played a 343 significant role in the huge drop in antibiotic utilisation rates between 2018 and 2019. 344 For example, there was already an annual 4.6% drop in antibiotic utilisation rate three 345 years before the launch of the antimicrobial intervention plan [28]. 346

347 Strengths

The reimbursement system in New Zealand captures greater than 95% of the 348 prescription coverage of older adults' census population, strengthening our study 349 findings' validity. This study also acts as a proxy measure of adherence to national 350 antibiotic prescribing policies and stewardship guidelines among older adults in New 351 Zealand. In addition, the validity of our findings was strengthened by using the ARIMA 352 models to perform the interrupted time series analysis to investigate the impact of the 353 antimicrobial resistance action plan on antibiotic utilisation. Previous studies have 354 355 demonstrated the utility and reliability of ARIMA models for evaluating population-level health interventions [18]. 356

357 Conclusion

358

This study provides valuable information on the consumption of systemic antibiotics among the 65 years or above sub-population of New Zealand. It has also shown the effectiveness of the antimicrobial resistance action plan introduced by the government of New Zealand to mitigate antibiotic resistance by reducing inappropriate antimicrobial utilisation. The ITS analysis has demonstrated that this intervention hugely impacted the antibiotic utilisation rate among older adults. As a result, there was a significant reduction in the overall utilisation of systematic antibiotics between

366 2005 and 2019 among older adults in New Zealand. However, there were some age 367 and sex differences in the consumption rates of antibiotics among the studied 368 population. Further studies are required to determine whether the reduced 369 consumption rates of antibiotics are associated with reduced rates of antibiotic-370 associated adverse drug events such as acute kidney injury and haematological 371 abnormalities.

372

Ethics statement: The Departmental Research and Ethics Officer at the University
of Bath assessed the ethical implications of research activity (EIRA) and approved
this study on behalf of the University of Bath's Research, Integrity, and Ethics
committee. Approval number EIRA 1-4048.

377 Acknowledgement

378

The authors thank the Analytical Services, Ministry of Health of New Zealand, for supplying the data extracted from the Pharms database.

381

382 Author contributions

TC (Bath) serves as the first author of the manuscript. He led all the stages of the development of this manuscript while PN supervised. TC (Otago), TC (Bath), and PN contributed to statistical analysis, interpretation of results, and manuscript revision. SR and HJ also contributed to interpreting the results and manuscript revision. All authors approved the final manuscript.

388

389 **Conflict of interest**: The authors have no conflicts of interest to declare

390

391 **Funding:** No funding was received

392

393 **Data availability:** The data is owned by the Analytical Services, Ministry of Health,

New Zealand, so supporting data is not available

396 **References**

397

1. Pulia MS, Keller SC, Crnich CJ, Jump RLP, Yoshikawa TT. Antibiotic

Stewardship for Older Adults in Ambulatory Care Settings: Addressing an UnmetChallenge. J Am Geriatr Soc. 2020;68(2):244-9.

2. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse
Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med.

403 2017;177(9):1308-15.

404 3. Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, et al.

Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in

406 Hospitalized Patients: A Single-center Study. Intern Med. 2019;58(18):2621-5.

407 4. King LM, Bartoces M, Fleming-Dutra KE, Roberts RM, Hicks LA. Changes in
408 US Outpatient Antibiotic Prescriptions From 2011-2016. Clin Infect Dis.
409 2020;70(2):270.7

409 2020;70(3):370-7.

5. Kabbani S, Palms D, Bartoces M, Stone N, Hicks LA. Outpatient Antibiotic
Prescribing for Older Adults in the United States: 2011 to 2014. J Am Geriatr Soc.
2018;66(10):1998-2002.

6. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, Jr.,
et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory

415 Care Visits, 2010-2011. Jama. 2016;315(17):1864-73.

7. Silverman M, Povitz M, Sontrop JM, Li L, Richard L, Cejic S, et al. Antibiotic
Prescribing for Nonbacterial Acute Upper Respiratory Infections in Elderly Persons.
Ann Intern Med. 2017;166(11):765-74.

8. Schmidt ML, Spencer MD, Davidson LE. Patient, Provider, and Practice

420 Characteristics Associated with Inappropriate Antimicrobial Prescribing in

421 Ambulatory Practices. Infect Control Hosp Epidemiol. 2018;39(3):307-15.

422 9. Tanner LA, Baum C. Spontaneous adverse reaction reporting in the elderly.
423 Lancet. 1988;2(8610):580.

10. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits

for antibiotic-associated adverse events. Clin Infect Dis. 2008;47(6):735-43.

11. Sakoulas G. Adverse effects of fluoroquinolones: where do we stand now.

427 NEJM Journal Watch. 2019;13.

428 12. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, et al.

- Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and
 death. Ann Fam Med. 2014;12(2):121-7.
- 431 13. Robertson J, Vlahović-Palčevski V, Iwamoto K, Högberg LD, Godman B,
- 432 Monnet DL, et al. Variations in the Consumption of Antimicrobial Medicines in the
- 433 European Region, 2014-2018: Findings and Implications from ESAC-Net and WHO
- 434 Europe. Front Pharmacol. 2021;12:639207.
- 435 14. Andersson K, van Driel M, Hedin K, Hollingworth S, Merlo G. Antibiotic use in
 436 Australian and Swedish primary care: a cross-country comparison. Scand J Prim
 437 Health Care. 2022:1-9.
- 438 15. Williamson DA, Roos R, Verrall A, Smith A, Thomas MG. Trends,
- demographics and disparities in outpatient antibiotic consumption in New Zealand: a
 national study. J Antimicrob Chemother. 2016;71(12):3593-8.
- 16. Tomlin AM, Woods DJ, Reid JJ, Tilyard MW. Trends in prescription medicine
 use by older people in New Zealand 2010- 2015: a national population-based study.
 N Z Med J. 2020;133(1513):61-72.
- 444 17. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for
 445 the evaluation of public health interventions: a tutorial. Int J Epidemiol.
- 446 2017;46(1):348-55.
- 18. Schaffer AL, Dobbins TA, Pearson SA. Interrupted time series analysis using
 autoregressive integrated moving average (ARIMA) models: a guide for evaluating
- large-scale health interventions. BMC Med Res Methodol. 2021;21(1):58.
- 450 19. Ministry of Health. Pharmaceutical collection. Publicly funded pharmaceutical
 451 dispensings between 1 January 2005 and 31 December 2016. 2017.
- 452 20. collection. MoHP. Publicly funded pharmaceutical dispensings between 1 July
 453 2012 and 31 December 2019 for a selected cohort. 2020.
- 454 21. Narayan SW, Hilmer SN, Horsburgh S, Nishtala PS. Anticholinergic
- 455 component of the Drug Burden Index and the Anticholinergic Drug Scale as
- 456 measures of anticholinergic exposure in older people in New Zealand: a population-
- 457 level study. Drugs Aging. 2013;30(11):927-34.
- 458 22. Who Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index
- 459 2022 [cited 2022 31/05/2022]. Available from:
- 460 <u>https://www.whocc.no/atc_ddd_index/</u>.

23. R Core Team. R: A language and environment for statistical computing.: R 461 Foundation for Statistical Computing, Vienna, Austria.; 2022 [updated April 2022; 462 cited 2022 05/05/2022]. R-4.2.0: [Available from: https://www.R-project.org/. 463 24. Ministry of Health and Ministry for Primary Industries. New Zealand 464 Antimicrobial Resistance Action Plan. In: Industries. MoHaMfP, editor. Wellington: 465 Ministry of Health; 2017. 466 25. Thomas M. Upfront: Time to reduce antibiotic prescribing – NOW. Best 467 Practice Journal New Zealand. 2015(68). 468 469 26. Williamson DA, Roos, R.F., Verrall, A. Antibiotic Consumption in New Zealand, 2006-2014. In: Zealand. TIoESaRLPN, editor. Porirua2016. 470 27. Best Practice Advocacy Centre New Zealand. National Report: Overview of 471 national dispensing during 2020 2021 [cited 2022 21/10/2022]. Available from: 472 https://bpac.org.nz/report/2020/national-dispensing.aspx#dispensing. 473 28. Thomas M, Tomlin A, Duffy E, Tilyard M. Reduced community antibiotic 474 dispensing in New Zealand during 2015-2018: marked variation in relation to primary 475 health organisation. N Z Med J. 2020;133(1518):33-42. 476 29. Ministry of Health and Ministry for Primary Industries. Antimicrobial 477 478 Resistance: New Zealand's current situation and identified areas for action. In: Industries MoHaMfP, editor. Wellington: Ministry of Health; 2017. 479 30. Olesen SW, Barnett ML, MacFadden DR, Lipsitch M, Grad YH. Trends in 480 outpatient antibiotic use and prescribing practice among US older adults, 2011-15: 481 observational study. Bmj. 2018;362:k3155. 482 Auta A, Hadi MA, Oga E, Adewuyi EO, Abdu-Aguye SN, Adeloye D, et al. 31. 483 Global access to antibiotics without prescription in community pharmacies: A 484 systematic review and meta-analysis. J Infect. 2019;78(1):8-18. 485 32. Browne AJ, Chipeta MG, Haines-Woodhouse G, Kumaran EPA, Hamadani 486 BHK, Zaraa S, et al. Global antibiotic consumption and usage in humans, 2000-18: a 487 spatial modelling study. Lancet Planet Health. 2021;5(12):e893-e904. 488 Márquez EJ, Chung CH, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, et 33. 489 al. Sexual-dimorphism in human immune system aging. Nat Commun. 490 2020;11(1):751. 491 Donald S, Sharples K, Barson D, Horsburgh S, Parkin L. Patterns of 34. 492

- 493 prescription medicine dispensing before and during pregnancy in New Zealand,
- 494 2005-2015. PLoS One. 2020;15(6):e0234153.




Figure 1: Systemic antibacterial utilisation by antibiotic class, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand.

Figure 1





Figure 2: Systemic antibacterial class consumption by age group, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand

Figure 2



1

- 2 Figure 3: Systemic antibacterial class consumption by age group and sex, expressed as defined daily doses per thousand older
- 3 people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand.

Interrupted time series analysis: Final ARIMA model




Figure 4: Final ARIMA model showing predicted values in the absence of antimicrobial resistance action plan (counterfactual) compared to observed values. Step = -0.2206 (95% CI: -0.4619 - 0.0207).

Ramp = -0.0029 (95% CI: -0.0097 - 0.0039)

Key:

Counterfactual = Red. Observed values = Blue. Intervention date = Grey dotted vertical

Figure 4